Clinical Practice Session
Novel Treatments for Resistant Hypertension in Advanced CKD
November 03, 2022 | 02:00 PM - 04:00 PM
Location: W311, Orange County Convention Center, West Building
Session Description
Resistant hypertension is a major contributor to the excess morbidity and mortality in patients with advanced CKD. This session presents novel agents and device therapy for the treatment of resistant hypertension. Particular emphasis is given to the nonsteroidal mineralocorticoid receptor blocker (KBP-5074), combined endothelin A and B antagonists, and centrally acting aminopeptidase inhibitors. In addition, updates are given on the use of kidney denervation.
Learning Objective(s)
- Implement the use of a novel nonsteroidal mineralocorticoid receptor blocker (KBP-5074) in patients with advanced CKD and resistant hypertension
- Explain the rationale for using combined endothelin A and B receptor antagonists for the treatment of resistant hypertension in patients with advanced CKD
- Describe the use of centrally acting aminopeptidase inhibitors for the treatment of resistant hypertension in Black patients with CKD
- Summarize the current state of kidney denervation therapy as a treatment modality for patients with CKD and resistant hypertension
Learning Pathway(s)
- Hypertension and Cardiorenal Disorders
Moderators
- George L. Bakris, MD, FASN
- Karen A. Griffin, MD, FASN
Presentations
- Nonsteroidal Mineralocorticoid Receptor Blocker (KBP-5074) for Hypertension in Stage 4 CKD
02:00 PM - 02:30 PM
Pablo E. Pergola, MD, PhD
- Combined Endothelin A and B Antagonists in Patients with Stage 4 CKD
02:30 PM - 03:00 PM
Ernesto L. Schiffrin, MD, PhD
- Effects of Firibastat, a First-in-Class Centrally Acting Aminopeptidase Inhibitor on Resistant Hypertension
03:00 PM - 03:30 PM
Michel Azizi, MD, PhD
- Kidney Denervation for Hypertension: Where We Are Now
03:30 PM - 04:00 PM
Raymond R. Townsend, MD
